Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 26 |
| Active Pipeline (Recruiting Now) | 7 (4) |
| Completed vs Stopped Early | 9 / 10 (38.5%) |
| Median Closed Actual Enrollment | 32 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, MI | 3 |
| Azienda Ospedaliero Universitaria di Parma | Parma | 2 |
| Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico | Milan | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06680050 | Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastase | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Mario Negri Institute for Pharmacological Research Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.